Bioventus (BVS) AI Stock Analysis

Bioventus

(NASDAQ:BVS)

Select Model

Rating:66Neutral

Price Target:$14.00▲(4.87% Upside)

Action:downgraded

Date:11/03/26

The score is driven primarily by improving financial performance (profitability recovery, strong free cash flow, and declining debt) and a generally positive earnings outlook with reaffirmed EPS and cash-flow guidance. These positives are tempered by weaker near-term technicals, inconsistent revenue history plus the recent revenue-guidance cut, and uncertainty tied to the ongoing strategic review.

Positive Factors

Strong cash generationOperating and free cash flow closely tracking net income indicates that reported earnings are converting effectively into cash. This supports debt repayment, continued investment in growth initiatives, and greater financial resilience over the next several quarters.

Negative Factors

BGS weakness and guidance cutThe BGS decline and associated revenue-guidance reduction indicate that competitive dynamics, procedure softness, and distributor timing are affecting a meaningful business area. Persistent weakness could limit consolidated growth and make near-term execution more dependent on other segments.

Bioventus Key Performance Indicators (KPIs)

Revenue by SegmentAnalyzes revenue from different business segments, highlighting which areas are driving growth and which may need strategic adjustments to improve performance.

Chart Insights

Pain Treatments remains the largest and primary growth lever—recent quarters show strong spikes including a big late‑2025 jump, but management cautioned Q1 was aided by a one‑time rebate and distributor timing so underlying Pain growth is mid‑single digits. Surgical Solutions is a steadier, durable grower with management expecting H2 acceleration after a planned slow Q1. Restorative Therapies has materially rolled off from its 2021–22 peaks and now contributes far less, prompting reallocations into PNS/PRP/Ultrasonics to drive future upside.

Data provided by:

The Fly

Bioventus (BVS) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $898.21M
Dividend Yield: ―
Average Volume (3M): 554.96K
Price to Earnings (P/E): 15.5
Beta (1Y): 0.56
Revenue Growth: 3.14%
EPS Growth: ―
Country: US
Employees: 950
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Bioventus Business Overview & Revenue Model

Company Description

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular an...

How the Company Makes Money

Bioventus generates revenue by selling musculoskeletal-focused medical devices and related products through a mix of direct sales and distribution channels, primarily to healthcare providers (e.g., orthopedic and sports-medicine physicians), hospital...

Bioventus Earnings Call Summary

Earnings Call Date:Nov 01, 2026(Q3-2026)|% Change Since:1.52%|Next Earnings Date:May 15, 2023

Earnings Call SentimentPositive

The call was broadly constructive and positive. The company reported revenue growth, expanding adjusted EBITDA margin, double-digit growth in Ultrasonics and international revenue, improving PRP and PNS indicators, strong cash generation and significant debt repayment. These positives outweighed the BGS weakness, lower full-year revenue guidance, Exogen-related softness, slightly lower gross margin and the unresolved strategic review.

Positive Updates

Revenue Growth Led by Pain Treatments

Third-quarter revenue was $142 million, up 3% year over year, driven by strong performance in pain treatments. Global pain-treatment revenue increased 6% to $71 million and was up 9% year to date, supported by Duralane, PRP and PNS.

Negative Updates

BGS Revenue Decline and Headwinds

Bone graft substitutes revenue declined 6% in the third quarter and came in lower than expected. The result reflected modest softness in spine procedures, temporary delays in adding new distributors and competitive dynamics in the synthetic market. Management stated that strong volume from new large IDN accounts was offset by these factors.

Company Guidance

Bioventus expects 2026 revenue of $590 million to $595 million, reflecting mid single digit revenue growth in Q4 and sequential acceleration; full-year adjusted earnings per share guidance is $0.75 to $0.79 per diluted share, while cash from operations guidance and adjusted cash from operations are both $84 million to $89 million. Full-year adjusted EBITDA margin is expected to be above the prior year level, net leverage ratio is expected to be below 1.5x by the end of this year, international revenue is expected to generate more than 20% growth in the fourth quarter and continued excellent growth in 2027, and Exogen growth is expected to be low single digits this year and low single digit to mid single digit going forward. The company expects strong double digit growth in international in the fourth quarter and for the full year, strong double digit growth in Ultrasonics in the fourth quarter and into 2027, PNS to scale to over $100 million in the coming years, and growth-driver investments to reach almost $15 million in 2026.

Bioventus Financial Statement Overview

Summary

Financials are improving, led by a meaningful rebound in profitability (TTM net margin ~9.4% vs ~4.0% in 2025) and strong cash generation (TTM FCF ~$102.6M closely tracking net income). Balance sheet direction is positive with declining debt and rising equity, but the company’s recent history shows earnings volatility, previously elevated leverage, and inconsistent revenue momentum, which keeps the score from moving higher.

Income Statement

66Positive

Balance Sheet

63Positive

Cash Flow

74Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Mar 2023	Dec 2021
Income Statement
Total Revenue	581.85M	568.09M	573.28M	512.35M	512.12M	430.90M
Gross Profit	395.64M	382.43M	388.23M	328.19M	331.08M	302.71M
EBITDA	103.76M	99.21M	39.22M	-23.07M	-121.61M	45.48M
Net Income	54.46M	22.73M	-33.54M	-156.23M	-158.70M	19.38M
Balance Sheet
Total Assets	673.35M	683.56M	727.96M	810.91M	1.37B	1.23B
Cash, Cash Equivalents and Short-Term Investments	29.46M	51.24M	41.58M	36.96M	30.19M	43.93M
Total Debt	263.75M	311.35M	335.63M	394.85M	418.07M	357.68M
Total Liabilities	395.93M	455.11M	542.35M	589.79M	960.43M	692.07M
Stockholders Equity	228.31M	184.10M	147.94M	173.59M	325.24M	458.92M
Cash Flow
Free Cash Flow	94.29M	71.41M	37.79M	7.98M	-15.02M	2.10M
Operating Cash Flow	96.87M	73.98M	38.80M	15.34M	-13.54M	22.99M
Investing Cash Flow	-4.09M	-3.25M	22.96M	15.81M	-116.44M	-283.76M
Financing Cash Flow	-95.00M	-61.44M	-54.58M	-26.65M	62.08M	273.37M

Bioventus Technical Analysis

Technical Analysis SentimentNegative

Last Price13.35

Price Trends

50DMA13.68Negative

100DMA12.77Positive

200DMA10.93Positive

Market Momentum

MACD0.15Positive

RSI42.47Neutral

STOCH27.48Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BVS, the sentiment is Negative. The current price of 13.35 is below the 20-day moving average (MA) of 13.81, below the 50-day MA of 13.68, and above the 200-day MA of 10.93, indicating a neutral trend. The MACD of 0.15 indicates Positive momentum. The RSI at 42.47 is Neutral, neither overbought nor oversold. The STOCH value of 27.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BVS.

Bioventus Risk Analysis

Bioventus disclosed 81 risk factors in its most recent earnings report. Bioventus reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

1 New Risk

1.In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors and other cautionary statements described under the heading Risk Factors included in our 2025 10-K, which could materially affect our businesses, financial condition, or future results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may adversely affect our business, financial condition, or future results. There have been no material changes in our risk factors from those described in our 2025 10-K.Q1, 2026

Bioventus Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

BVS against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ZBH	69Neutral	$18.03B	23.57	6.36%	0.99%	8.62%	0.09%
BVS	66Neutral	$1.12B	15.54	28.39%	―	3.14%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ENOV	50Neutral	$1.15B	-1.06	-68.17%	―	4.89%	-30.14%
OFIX	50Neutral	$369.44M	-5.70	-14.05%	―	2.99%	51.77%
ATEC	49Neutral	$1.09B	-13.05	-547.17%	―	15.34%	46.31%
IART	44Neutral	$991.96M	81.11	1.24%	―	0.84%	―

* Healthcare Sector Average

Performance Comparison

BVS and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
BVS	Bioventus, Inc.	13.15	5.77	78.18%
ATEC	Alphatec	7.31	-12.41	-62.93%
ENOV	Enovis Corporation	20.62	-10.87	-34.52%
IART	Integra Lifesciences	13.61	2.21	19.39%
OFIX	Orthofix Medical Inc.	8.75	-6.22	-41.55%
ZBH	Zimmer Biomet Holdings	97.35	10.73	12.38%

Bioventus Corporate Events

Business Operations and StrategyFinancial DisclosuresM&A Transactions

Bioventus Reports Solid Q2 Results Amid Strategic Review

Positive

Aug 5, 2026

On August 5, 2026, Bioventus reported second-quarter 2026 results showing worldwide revenue up 4% to $153.2 million, driven by double-digit growth in Pain Treatments, and net income rising to $33.4 million from $7.5 million a year earlier, aided by t...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 03, 2026

Bioventus AI Stock Analysis